FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee will convene July 19 to mediate separate conclusions reached by three different agency divisions regarding the safety of Valeant Pharmaceuticals International Inc.’s plaque psoriasis candidate Siliq (brodalumab).
The suicides of six clinical trial subjects taking the drug, along with 40 brodalumab-treated patients who exhibited suicidal ideation and...




